Is culture-free pneumonia testing finally viable as Pattern Bioscience nears regulatory submission
Pattern Bioscience advances rapid pneumonia diagnostics toward FDA clearance. Discover what this means for ICU care and antibiotic resistance.
Triana Biomedicines tests degradation-first approach in ALK positive lung cancer with TRI-611
Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis.
LivaNova PLC expands sleep apnea eligibility as aura6000 gains FDA approval without CCC limits
LivaNova PLC secures FDA approval for aura6000. Discover how it could reshape sleep apnea treatment and expand patient eligibility.
Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation
ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.
Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics
Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.
Can low-dose radiotherapy reshape osteoarthritis care after Siemens Healthineers’ FDA clearance
Siemens Healthineers expands TrueBeam into osteoarthritis care with FDA clearance. Find out how radiotherapy could reshape chronic pain treatment.
Cathy Tie’s Origin Genomics targets germline gene correction under US IRB oversight
Origin Genomics launches in New York to advance germline gene correction and MRT under IRB oversight. Analyse what it means for US gene editing regulation.
Oral Pompe therapy S-606001 moves to Phase 2 as Shionogi expands rare disease focus
Shionogi’s S-606001 enters global Phase 2 as the first oral GYS1 inhibitor tested as an add-on to ERT in late-onset Pompe disease. Read the analysis.
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward
GenSight Biologics begins treating ND4-LHON patients under France’s AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.
Novartis acquires SNV4818 from Synnovation in $3bn deal to reclaim ground in mutant PI3Ka breast cancer space
Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.